Main Line Fertility is the only fertility center in the greater Philadelphia area that offers its patients non-invasive preimplantation genetic testing (PGT) of embryos. For patients undergoing in vitro fertilization, non-invasive PGT increases the possibility of a successful pregnancy and can help identify embryos that have genetic abnormalities which can result in a miscarriage or certain genetic disorders. Additionally, genetic testing allows patients to know the gender of their embryos if they wish.


Unlike the traditional embryo screening which requires an embryo biopsy, non-invasive PGT is a minimally invasive procedure that only removes a small sample of culture media surrounding the embryo, and does not involve taking cells from the embryo itself, thus causing little to no stress on embryo development.


      • Female patients over the age of 34
      • Patients who have experienced repeated IVF failure
      • Patients or partners who are carriers or affected by genetic disorders that can be passed down to a child
      • Patients or partners who are carriers of a translocation
      • Patients with a history of miscarriage
      • Patients who do not want to incur cryostorage fees of chromosomally abnormal embryos
      • Patients who wish to reduce their risk of miscarriage and genetic abnormalities
      • Patients interested in gender selection for family balancing

“We chose to do non-invasive preimplantation genetic testing on our embryos because we wanted to have the best chance for a successful and healthy pregnancy”

– Ashley & Mike


Screens for aneuploidy which is too few or too many chromosomes. Aneuploidy can lead to IVF failure or miscarriage and occurs randomly in embryos during development.


Diagnoses specific genetic disorders in embryos such as Cystic Fibrosis, Fragile X, Muscular Dystrophy, BRCA, Thalassemia, Tay Sachs and others.


Identifies whether the embryo has a structural rearrangement of its chromosomal matter. PGT-SR can be performed to improve the chance of establishing a healthy pregnancy for people with a chromosomal translocation.


The cost of preimplantation genetic testing begins at $2,500 and includes the day 3 embryo preparation, DNA sampling of the blastocyst’s culture medium and packaging of the culture samples. The final cost of PGT is dependent on how many embryos are tested.


Not all embryos created will develop to the blastocyst stage. Only good quality blastocysts on day 5, day 6 or day 7 of culture can be biopsied.

PGT reduces the chance of having a chromosomally abnormal pregnancy but does not replace prenatal testing.

Your Main Line Fertility physician will partner with you to decide if PGT is beneficial based on your medical history and personal preferences.

Some insurances will cover PGT. Patients should contact their insurance carriers to determine coverage prior to their IVF cycle.

PGT is able to identify the gender of your embryo(s), and if you wish to know the gender we can share that information with you. Patients can specify the gender they prefer for embryo transfer. We are not able to change or guarantee a gender.

While non-invasive PGT can greatly reduce your chance of experiencing a miscarriage or having a child with a genetic disorder, it cannot guarantee that they will not occur.

Questions about non-invasive preimplantation genetic testing?
Ask our patient care advocate